TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03784404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal aspiration
Description: under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal aspiration and surgicel injection
Description: under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracytoplasmic sperm injection
Description: Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance.
Study: NCT05566990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIV-GAMMA SN Inj.10%
Description: LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.
Study: NCT01295515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha 2b (PEGINTRON)
Description: pegylated preparation of interferon alpha 2b
Study: NCT03114215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: capsules 100mg lactose 3 times per day
Study: NCT04514978

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood donation and blood transfusion
Description: 24 subjects (12 female, 12 male) is phlebotomized and four weeks later \~130 mL packed red blood cells are re-infused in the same subjects.
Study: NCT00659373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study: NCT01735214

Intervention type: DRUG
Intervention: Prostaglandin Analogue -Containing IOP-Lowering Therapy
Description: Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
Study: NCT01607320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
Study: NCT01672242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
Study: NCT03294343

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up
Description: Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
Study: NCT03498911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery
Description: The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucogingival surgery
Description: The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
Study: NCT03145857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68]Ga-HA-DOTATATE
Description: All participants will be injected with \[68\]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
Study: NCT04030806

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mirror therapy intervention and control intervention
Description: The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy intervention and control intervention
Description: The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation.
Study: NCT03031873

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI perfusion imaging
Description: Evaluate the evolution of progressive obliteration of the AVM nidus
Study: NCT03021733

Intervention type: PROCEDURE
Intervention: Operative management
Description: Rotator cuff surgery
Study: NCT01404689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: normal saline
Description: 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
Study: NCT04312958

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT03527927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any LABA/LAMA
Description: Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
Study: NCT01520727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: single ascending doses in up to 8 sequential groups of 8 healthy young male subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose
Study: NCT00417911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib
Description: Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
Study: NCT00515021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Morning)
Description: Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Morning)
Description: Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Night-time)
Description: Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Night-time)
Description: Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
Study: NCT04662957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic mixture of four Bifidobacterium, five Lactobacillus and one Streptococcus species or placebo
Description: Oral supplementation with multi-strain probiotic preparation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin as placebo
Study: NCT03525912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: continuous infusion of low dose ketamine for postoperative pain
Study: NCT03154918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIDE
Description: The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
Study: NCT03798366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: Film-coated tablets of GLPG1690 for oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablets of GLPG1690 matching placebo for oral use.
Study: NCT00999882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
Study: NCT03438773

Intervention type: DRUG
Group type: OTHER
Intervention: Envarsus
Description: Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
Study: NCT04134689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DOT Selfie Intervention
Description: This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person DOT
Description: Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
Study: NCT02403089

Intervention type: OTHER
Intervention: Tubes fund recovery blood count
Description: Tubes fund recovery of blood counts among newborns

Intervention type: OTHER
Intervention: the rest of the blood test and stool sample
Description: blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
Study: NCT02871024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toraymyxin
Description: Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
Study: NCT01738568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Description: High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at \~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Control
Description: Sedentary control participants will not perform any regular exercise for 12-weeks.
Study: NCT00760994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential acceptance
Description: The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert \& Forsyth, 2005; Hayes, Strosahl, \& Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, \& Barlow, 2004).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive restructuring
Description: The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-intervention control: Nutrition information
Description: The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
Study: NCT06234891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nsaid
Description: Medical treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nsaid
Description: Medical treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phsiotheraphy
Description: Nsaid and phsiotheraphy (hotpack-ultrasound therapy- tens)
Study: NCT00455780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: Weight loss using CBT and meal replacements
Study: NCT03626688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralinepag
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02371473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide-placebo
Description: The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-acetazolamide
Description: The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
Study: NCT04005352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Description: Intra-vitreal injection
Study: NCT00607607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
Study: NCT04005352

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2 mg
Description: Intra-vitreal injection
Study: NCT02469324

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training
Description: see above
Study: NCT02382640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat extended-release (XR) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat extended-release (XR) capsules
Study: NCT01371474

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT02382640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat extended-release (XR) capsules
Study: NCT02647346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily use of podimetrics smart-foot mat
Study: NCT02272179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: As Safe As Possible
Description: The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
Study: NCT02382640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox Advance Regular Strength liquid
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox Advance Regular Strength liquid
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox Advance Regular Strength liquid
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maalox Advance Regular Strength liquid
Description: Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
Study: NCT01079104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepa Wash
Description: Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)
Study: NCT02272179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brite
Description: Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.